Overview / Abstract: |
Target Audience This activity has been designed to address the educational needs of nurse practitioners (NPs) and physician assistants who practice across a range of healthcare settings, many of which accommodate a high volume of patients who are at high risk for influenza-related complications (eg, primary care, infectious diseases, women’s health, pediatrics, and geriatrics). The initiative might also benefit other clinicians who are involved or interested in the prevention and management of influenza. Program Overview After a 20-year period of stagnation, the influenza management landscape has been revitalized with the recent approval of a first-in-class antiviral agent. this educational activity will provide an evidence-based update on influenza care, addressing the importance of differentiating influenza from other infections, identifying patients who are at high risk of influenza-related complications, using antivirals appropriately to head off serious influenza sequelae, and differentiating among conventional and novel antivirals to make evidence-based decisions about influenza treatment and prophylaxis. Learning Objectives Upon proper completion of this activity, participants should be better able to: Identify appropriate candidates for antiviral therapy based on risk of influenza-related complications, in accordance with current guideline recommendations |
Expiration |
Oct 31, 2021 |
Discipline(s) |
Nurse Practitioner |
Format |
Online |
Credits / Hours |
1.00 AAPA Category 1 CME credit |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Faculty Steering Committee Ruth M. Carrico, PhD, DNP, FNP-C, CIC, FSHEA, FNAP Laura Gunder McClary, DHSc, PA-C Charles Vega, MD |
Sponsors / Supporters / Grant Providers |
Genentech, a member of the Roche Group. |
Keywords / Search Terms |
Relias LLC FREE CME., Relias LLC., Influenza Free CE CME |